Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Depreciation & Amortization (CF) (2018 - 2025)

Historic Depreciation & Amortization (CF) for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $10.1 million.

  • 10x Genomics' Depreciation & Amortization (CF) rose 1502.86% to $10.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $36.2 million, marking a year-over-year increase of 89.19%. This contributed to the annual value of $36.2 million for FY2025, which is 89.19% up from last year.
  • Per 10x Genomics' latest filing, its Depreciation & Amortization (CF) stood at $10.1 million for Q4 2025, which was up 1502.86% from $10.3 million recorded in Q3 2025.
  • 10x Genomics' 5-year Depreciation & Amortization (CF) high stood at $10.3 million for Q3 2025, and its period low was $4.8 million during Q1 2021.
  • Its 5-year average for Depreciation & Amortization (CF) is $7.7 million, with a median of $7.9 million in 2025.
  • In the last 5 years, 10x Genomics' Depreciation & Amortization (CF) surged by 5857.46% in 2021 and then crashed by 1288.6% in 2025.
  • Over the past 5 years, 10x Genomics' Depreciation & Amortization (CF) (Quarter) stood at $5.8 million in 2021, then increased by 12.8% to $6.5 million in 2022, then surged by 49.01% to $9.7 million in 2023, then fell by 9.95% to $8.8 million in 2024, then increased by 15.03% to $10.1 million in 2025.
  • Its Depreciation & Amortization (CF) was $10.1 million in Q4 2025, compared to $10.3 million in Q3 2025 and $7.8 million in Q2 2025.